Evidence map›Paper›PMID 40177275›Full record

ArticleFrontiers in medicine2025

Localization of fluorescent gold nanoparticles throughout the eye after topical administration.

Gabrielle Raîche-Marcoux, Sébastien Méthot, Ange Tchatchouang, Camille Bettoli, Cloé Maranda, Alexis Loiseau, Stéphanie Proulx, Patrick J Rochette, Emilie Genin, Élodie Boisselier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabrielle Raîche-MarcouxCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Sébastien MéthotCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Ange TchatchouangCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Camille BettoliUniversité de Bordeaux, CNRS, Bordeaux INP, ISM, UMR 5255, Talence, France.
Cloé MarandaCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Alexis LoiseauCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Stéphanie ProulxCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Patrick J RochetteCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Emilie GeninUniversité de Bordeaux, CNRS, Bordeaux INP, ISM, UMR 5255, Talence, France.
Élodie BoisselierCHU de Québec Research Center-Université Laval and Department of Ophthalmology and Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human eye is a highly intricate sensory organ. When a condition requiring treatment occurs, eyedrops, which represent 90% of all ophthalmic treatments, are most frequently used. However, eyedrops are associated with low bioavailability, with less than 0.02% of therapeutic molecules reaching the anterior chamber. Thus, new delivery systems are required to ensure sufficient drug concentration over time at the target site. Gold nanoparticles are a promising avenue for drug delivery; however, they can be difficult to track in biological systems. Fluorescent gold nanoparticles, which have the same ultrastability and biocompatibility as their nonfluorescent counterpart, could act as an effective imaging tool to study their localization throughout the eye after administration. Thus, this study (1) synthesized and characterized fluorescent gold nanoparticles, (2) validated similar properties between nonfluorescent and fluorescent gold nanoparticles, and (3) determined their localization in the eye after topical application on

Indexed as

biodistributionclick chemistryfluorescence imaginggold nanoparticlesophthalmology

Identifiers

PMID40177275
PMCPMC11961937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.